CheKine™ Micro Total Cholesterol Assay Kit: Illuminating Cardiovascular Risk, Metabolic Syndrome, and Beyond

TC: The Integrated Readout of Whole-Body Cholesterol Homeostasis

Total cholesterol (TC)—the sum of free cholesterol and cholesterol esters circulating in lipoproteins—remains the cornerstone of cardiovascular risk stratification, with clinical guidelines recommending TC levels below 200 mg/dL (5.18 mmol/L) for optimal heart health[reference:64]. TC reflects the balance between hepatic de novo synthesis (via HMG-CoA reductase), intestinal absorption (via NPC1L1), and reverse cholesterol transport (via HDL)[reference:65]. Beyond cardiovascular risk, dysregulated TC metabolism underpins Alzheimer's disease, cancer, and non-alcoholic fatty liver disease[reference:66].

Abbkine's CheKine™ Micro Total Cholesterol (TC) Assay Kit (KTB2220) replaces cumbersome legacy assays with a single-step, 10-minute, microplate-based colorimetric protocol that quantifies TC with picomole sensitivity, linearity from 0.1 to 10 mM, and negligible interference from triglycerides, bilirubin, or hemoglobin[reference:67].

Cardiovascular Research & Clinical Risk Assessment

TC > 240 mg/dL is associated with a 2-fold increased risk of coronary artery disease, while TC < 160 mg/dL may indicate malnutrition, hyperthyroidism, or liver failure[reference:68]. The KTB2220 kit enables:

• High-throughput cardiovascular risk screening in population studies
• Monitoring of lipid-lowering drug efficacy in preclinical models
• Assessment of TC in patient serum, plasma, and tissue homogenates[reference:69]
• Longitudinal tracking of TC changes in metabolic disease progression

Metabolic Syndrome & Diabetes Research

Dysregulated TC metabolism is a hallmark of metabolic syndrome. The kit supports:

• Evaluating TC in obesity and insulin resistance models
• Monitoring hepatic steatosis in NAFLD/NASH research
• Assessing TC as a biomarker for diabetes complications
• Screening compounds for cholesterol-lowering activity

Neurodegenerative Disease Research

Emerging evidence links TC dysregulation to Alzheimer's disease via amyloid-β production and membrane raft signaling[reference:70]. KTB2220 enables researchers to:

• Quantify TC in brain tissue homogenates and cerebrospinal fluid
• Study cholesterol metabolism in neurodegenerative disease models
• Evaluate the impact of cholesterol-lowering interventions on cognitive outcomes

Cancer Research

TC plays a critical role in membrane raft signaling and cancer cell proliferation[reference:71]. The kit supports:

• Measuring TC in tumor tissue and cancer cell lines
• Studying cholesterol metabolism in tumor microenvironments
• Evaluating the efficacy of cholesterol-targeting cancer therapies

The Dual-Enzyme Hydrolysis Advantage

Legacy TC assays fail in lipemic, hemolyzed, or tissue samples due to incomplete hydrolysis of cholesterol esters, turbidity from chylomicrons and VLDL, and cross-reactivity with other sterols[reference:72]. KTB2220 uses a dual-enzyme hydrolysis cascade and optimized detergents to eliminate interference from triglycerides, bilirubin, and hemoglobin, ensuring accurate TC quantification even in complex matrices[reference:73].

The Bottom Line

For researchers investigating TC in cardiovascular disease, metabolic syndrome, neurodegeneration, or cancer, KTB2220 delivers the speed (10 minutes), sensitivity (picomole), and specificity that modern translational research demands—without organic extraction, lengthy incubations, or dedicated spectrophotometers[reference:74].

📊 Your Research Area?
Cardiovascular Research | Metabolic Syndrome | Neurodegeneration | Cancer Biology | Drug Discovery

👉 Quantify total cholesterol with confidence. View Product